Leptin Gene Epigenetic Adaptation to Impaired Glucose Metabolism During Pregnancy by Bouchard, Luigi et al.
Leptin Gene Epigenetic Adaptation to
Impaired Glucose Metabolism During
Pregnancy
LUIGI BOUCHARD, PHD, MBA
1,2
ST´ EPHANIE THIBAULT, BSC
1,2
SIMON-PIERRE GUAY, BSC
1,2
MARTA SANTURE, PHD
1,2
ALEXANDRE MONPETIT, PHD
3
JULIE ST-PIERRE, MD, PHD
4
PATRICE PERRON, MD, MSC
2,5
DIANE BRISSON, PHD, CCRP
1,2
OBJECTIVE — To verify whether the leptin gene epigenetic (DNA methylation) proﬁle is
altered in the offspring of mothers with gestational impaired glucose tolerance (IGT).
RESEARCH DESIGN AND METHODS — Placental tissues and maternal and cord
bloodsampleswereobtainedfrom48womenattermincluding23subjectswithgestationalIGT.
Leptin DNA methylation, gene expression levels, and circulating concentration were measured
using the Sequenom EpiTYPER system, quantitative real-time RT-PCR, and enzyme-linked
immunosorbent assay, respectively. IGT was assessed after a 75-g oral glucose tolerance test
(OGTT) at 24–28 weeks of gestation.
RESULTS — We have shown that placental leptin gene DNA methylation levels were corre-
lated with glucose levels (2-h post-OGTT) in women with IGT (fetal side:  0.44, P  0.05;
maternal side: 0.53, P  0.01) and with decreased leptin gene expression (n  48;  
0.30, P  0.05) in the whole cohort. Placental leptin mRNA levels accounted for 16% of the
variance in maternal circulating leptin concentration (P  0.05).
CONCLUSIONS — IGT during pregnancy was associated with leptin gene DNA methyl-
ation adaptations with potential functional impacts. These epigenetic changes provide novel
mechanisms that could contribute to explaining the detrimental health effects associated with
fetal programming, such as long-term increased risk of developing obesity and type 2 diabetes.
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T
he fetal programming or Barker’s
hypothesis states that increased risk
of developing obesity and diabetes
in adulthood originates from fetal expo-
sure to detrimental environments such as
impairedglucosetolerance(IGT)andges-
tational diabetes mellitus (GDM) (1).
However, the molecular mechanisms
connectingpre-andperinatalexposureto
high glucose and insulin levels with an
increased long-term risk for health have
not yet been identiﬁed. Our hypothesis is
that the reprogramming of the newborn’s
energy metabolism through epigenetic
changes or adaptation in response to a
detrimental fetal environment contrib-
utes to explaining the long-term interin-
dividual variability in obesity and
diabetes risk. Therefore, comparing epi-
genetic differences between placental tis-
sues exposed or not to IGT could help
betterdeﬁnetheroleofepigeneticsinfetal
programming.
Epigenetics denotes molecular mech-
anismsindependentoftheDNAsequence
that refer to the heritable, but also revers-
ible, regulation of gene transcription (2).
Epigenetic marks are subjected to repro-
gramming in response to both stochastic
and environmental stimuli, such as
changes in diet and in utero environment
(3). Indeed, epigenetic marks can be mi-
totically stable and enduring, producing
long-term changes to gene expression (4)
and phenotypic variability. The DNA
methylationthattakesplaceatposition5
of the cytosine (C
met) pyrimidine ring is
the most stable and best understood epi-
genetic mark (5).
Leptin is a well-recognized obesity
and diabetes candidate gene for which
proximal promoter demethylation has
been shown to induce its gene tran-
scription in mature adipocytes (6). This
adipocytokine is involved in energy me-
tabolism and insulin sensitivity control
and is expressed and secreted by the pla-
centa during pregnancy (7). It follows
that leptin expression and plasma levels
are increased in obesity and diabetes, as
well as during pregnancy (8,9). Accord-
ingly, leptin is a strong candidate gene for
DNA methylation studies to verify
whether epigenetic mechanisms are af-
fected by glucose metabolism dysregula-
tion during pregnancy. The goals of this
study were, thus, to assess whether leptin
promoter DNA methylation shows adap-
tation (or variability) to IGT during preg-
nancy and to what extent these changes
have functional consequences on leptin
gene expression and circulating levels.
RESEARCH DESIGN AND
METHODS— Forty-eight women
withasingletonpregnancywererecruited
in the Saguenay area from a founder pop-
ulation of French-Canadian origin (self-
reported and conﬁrmed by the last name
and ﬁrst language). Women aged 40
years, with pregestational diabetes or
other disorders known to affect glucose
metabolism and those with a positive his-
tory of alcohol and/or drug abuse during
the current pregnancy were excluded.
The Chicoutimi Hospital Ethics Commit-
tee approved the project. All women pro-
vided written informed consent before
their inclusion in the study in accordance
with the Declaration of Helsinki.
Anthropometric variables (BMI and
waist and hip girth) and blood pressure
weremeasuredusingstandardizedproce-
dures(10).Glucosewasevaluatedusinga
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Coulter, Fullerton, CA), and insulin mea-
surements were performed using a radio-
immunoassay method (ADVIA Centaur,
Siemens). Serum leptin levels were mea-
suredusinganELISAasrecommendedby
the manufacturer (B-Bridge Interna-
tional). IGT was deﬁned as a 2-h glucose
7.8 mmol/l after a 75-g oral glucose tol-
erance test (OGTT) performed at 24–28
weeks of gestation. IGT in women was
controlledwithdietonly(n14)orwith
diet and insulin treatment (n  7). Two
mothers with IGT did not receive any
treatment.
Placental tissue sampling
Placental tissues were sampled in the
minutes after delivery (on average, 15
min) and kept in RNALater (Qiagen, Va-
lencia, CA) at 80°C until nucleic acid
extraction. Tissue biopsy samples were
taken from the fetal and the maternal
sides. The former consisted of the inter-
villous tissues and chorionic villi, and the
latter consisted mainly of fetal villous tis-
sue but may also contained tissue of ma-
ternal origin in the deciduas basalis (basal
plate). Analyses were performed on both
sides independently.
Leptin DNA methylation and mRNA
level measurements
DNAandRNAwerepuriﬁedusingtheAll
Prep DNA/RNA/Protein Mini Kit (Qia-
gen). RNA quality was assessed with Agi-
lent 2100 bioanalyzer RNA Nano Chips
(Agilent Technologies). On average, the
RNA showed good integrity (mean RNA
integrity number  7.63).
The gold standard Sequenom Epi-
TYPER system was used to determine
base-speciﬁc cytosine methylation levels
(11). This assay combines sodium bisul-
ﬁte DNA conversion chemistry (EpiTect
Bisulﬁte Kits; Qiagen), PCR ampliﬁcation
(Pyromark PCR kit; Qiagen) of the target
sequence, and base-speciﬁc cleavage. So-
dium bisulﬁte preferentially deaminates
unmethylated cytosine residues to thym-
ines,whereasmethylcytosinesremainun-
modiﬁed. Consequently, the base-
speciﬁc cleavage pattern will be affected
by the presence of methylated cytosine
within the original DNA sequence. The
cleavage products were analyzed by ma-
trix-assisted laser desorption ionization/
time of ﬂight mass spectrometry in which
the size ratio of the cleaved products pro-
vides quantitative methylation estimates
for each CpG site within the target se-
quence (11). The PCR primers for leptin
gene CpG island locus ampliﬁcation
were: 5-ACCACCCCCAAATTTT-3 and
5-AGATTAGTAGAGAAGGAGGA-
AGGA-3. One of the 96 DNA samples
(from the fetal side, IGT group) did not
amplify and was therefore not analyzed.
cDNA was generated from total RNA
usingarandomprimerhexamerprovided
with the High Capacity cDNA Archive kit
(Applied Biosystems, Foster City, CA).
Equal amounts of cDNA were run in du-
plicate and ampliﬁed in a 20-l reaction
containing 10 lo f2  Universal PCR
Master Mix (Applied Biosystems). Prim-
ers and TaqMan probes were obtained
from Applied Biosystems (Leptin:
Hs00174877_m1; Applied Biosystems).
Each sample was calibrated to the
YWHAZ housekeeping gene (endogenous
control; YWHAZ: Hs00237047_m1)
(12,13). Relative quantiﬁcation estima-
tions were performed using a 7500 Real-
TimePCRSystemasrecommendedbythe
manufacturer (Applied Biosystems).
Statistical analyses
Women with normal glucose tolerance
(NGT) and IGT were matched for mater-
nal age and ﬁrst trimester BMI. Student t
tests were applied to determine whether
mean group differences were statistically
signiﬁcant (P  0.05).
Fetal and maternal side mean locus
DNA methylation for each sample was
calculated among the cytosines with
mean DNA methylation levels 10%
across samples. Leptin/YWHAZ Ct ratio
(1/x) values were used for correlation
analyses.
First, the correlation between the de-
pendent variables (leptin DNA methyl-
ation, mRNA, and circulating levels) and
possible confounders (age, BMI, weight
changes, and insulin levels) was tested.
Leptin DNA methylation, mRNA, and
cord blood leptin levels were not corre-
latedwithanyofthesepossibleconfound-
ers. However, third trimester serum
leptin levels were correlated with ﬁrst tri-
mester BMI (0.39, P  0.01). On the
other hand, leptin cord blood levels were
found to be correlated with birth weight
(0.47, P  0.01). Accordingly, ﬁrst
trimester BMI and birth weight were in-
cludedinstatisticalmodelstestingassoci-
ation with third trimester serum and cord
blood leptin levels, respectively. Second,
statistical interaction between 2-h post-
OGTT glucose levels and IGT status has
been tested using the general linear
model. Signiﬁcant interactions were
found for leptin DNA methylation (fetal
side placenta: pinter  0.035; maternal
side placenta: pinter  0.029) but not for
leptin mRNA and circulating levels. Ac-
cordingly, correlation analyses for leptin
DNA methylation were conducted in
bothgroupsseparately.Correlationswere
tested using (partial) Spearman rank cor-
relation coefﬁcients (). P values were
two-sided. Statistical analyses were per-
formed using SAS software (version
9.1.3).
RESULTS— Table 1 shows women’s
and newborn’s physical and metabolic
characteristics. On average, women with
IGT gained less weight during pregnancy
and had decreased third trimester serum
leptin levels compared with the NGT
group. Cord blood leptin levels were de-
creased by almost 35% in the IGT group.
No other signiﬁcant difference between
the two groups was found. Nevertheless,
thirdtrimesterserumandcordbloodlep-
tin levels were negatively correlated with
2-h post-OGTT glucose levels (
0.57, P  0.0002 and  0.33, P 
0.043, respectively). Therefore, placental
leptin gene DNA methylation and expres-
sion levels have been assessed in both the
fetal and the maternal sides of the pla-
centatodeterminewhethertheywerealso
dysregulated according to 2-h post-
OGTT glucose levels and IGT status.
DNA methylation analyses targeted
the region of the leptin gene promoter
that has already been shown to be sub-
jected to demethylation associated with
leptin gene transcription activation dur-
ing preadipocyte maturation into adipo-
cyte (6). In fact, our analyses covered 31
of 42 cytosines located within the leptin
gene proximal promoter CpG island (Fig.
1, supplementary Table 1, available in
an online appendix at http://care.
diabetesjournals.org/cgi/content/full/
dc10-1024/DC1). Mean DNA methylation
levels 10% were observed for 20 and 26
CpG sites in the fetal and the maternal pla-
cental sides, respectively (Fig. 2). Within
the same placental side, CpG site pairwise
DNAmethylationcorrelationwasmoderate
to high ( 0.50, P  0.0001). However,
most of the correlation between fetal side
andmaternalsideCpGmethylationdidnot
reach the level of statistical signiﬁcance (
0.30, P  0.05) (data not shown).
No signiﬁcant difference was found
between groups for mean leptin gene
DNA methylation levels (Table 1). How-
ever, mean DNA methylation was found
to be signiﬁcantly correlated with glucose
levels (2-h post-OGTT) in the IGT group
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tion coefﬁcient showed opposite trends
between fetal and maternal placental tis-
sues (Fig. 3A and B). Of note, most CpG
sites provided very similar results when
analyzed separately (data not shown). No
correlation between leptin DNA methyl-
ation and glucose levels 2-h post-OGTT
was observed in the NGT group (n  25)
(data not shown).
The functional impacts of the ob-
served leptin gene DNA methylation vari-
ability on leptin gene transcription and
circulating levels were then assessed. On
the one hand, we found that the leptin
gene DNA methylation was associated
with decreased leptin gene mRNA levels
in both types of placental tissues (Fig. 3C
and D). On the other hand, although in-
creased leptin gene expression levels in
both the fetal and the maternal sides were
correlated with third trimester circulating
leptin levels (corrected for ﬁrst trimester
BMI) (Fig. 3E and F), the correlations be-
tween DNA methylation and circulating
(third trimester serum and cord blood)
concentrations were not found to be
signiﬁcant.
CONCLUSIONS — To the best of
our knowledge, this is the ﬁrst study in
humans focusing on the effect of gesta-
tional IGT (GDM) on the newborn epige-
netic proﬁle. The most important ﬁnding
is that placental DNA methylation is cor-
related with mother’s glycemia during
pregnancy. Interestingly, the leptin DNA
methylation showed adaptation only
within the group above the IGT diagnos-
ticcriteriathreshold(2-hpost-OGTTgly-
cemia 7.8 mmol/l), suggesting that the
leptin gene epigenetic proﬁle will be af-
fected by plasma glucose levels only
above a critical threshold.
Although the fetal programming hy-
pothesis is now well recognized, only a
fewstudieshaveprovideddirectevidence
that may support this concept. Of these,
Tobi et al. (14) have shown that DNA
methylation at several genome loci har-
boring genes implicated in growth,
development,andenergymetabolism(in-
cluding the leptin gene) was dysregulated
in human peripheral blood mononuclear
cells obtained from adult subjects who
had experienced prenatal exposure to
faminedecadesbefore.Wehaveobserved
that the correlations between 2-h post-
OGTT glucose and placental DNA meth-
ylation performed at the end of second
trimester suggest that IGT-related DNA
methylation adaptations are long lasting.
Although, DNA methylation adaptations
may have arisen during critical windows
offetaldevelopment(ﬁrsttrimester)(15),
we cannot rule out the possibility that the
placental DNA methylation adaptation
mayalsoberelatedtothemother’shyper-
glycemia at the end of gestation. Never-
theless, these results suggest that
dysregulation of the DNA methylation
proﬁle may potentially have long-term
consequences and suggest that the IGT-
related DNA methylation changes we
have observed have the potential to ac-
count for a long-term and possibly trans-
generational (16,17) risk to develop
obesity and type 2 diabetes associated
with fetal programming. Accordingly, if
GDM could be detected earlier and
treated rapidly, IGT would probably be
prevented along with epigenetic changes.
This ﬁnding reinforces the need to iden-
tify early GDM markers.
Interestingly, the correlations be-
tween 2-h post-OGTT glucose levels and
Figure 1—Leptin gene CpG island proximal promoter region. The forward CpG island sequence
is shown in italics and delimited by hyphens. The leptin exon 1 sequence is in bold type. Arrows
indicate both PCR primer sequences. Underlined cytosines have already been associated with
demethylation and leptin gene transcription activation (6). The sequence has been numbered
relative to the ﬁrst leptin gene codon (exon 2; Ensembl release 56 [September 2009]). The CpG
sites have been numbered relative to the 3 of the amplicon. The CpG no. 31 corresponds to 204
position in Melzner et al. (6).
Table 1—Characteristics of women and newborns
NGT IGT
n 25 23
Mother’s age (years) 28.1 	 0.7 29.0 	 0.7
1st T BMI (kg/m
2) 24.3 	 0.7 25.2 	 0.7
1st T fasting glycemia (mmol/l) 4.36 	 0.08 4.31 	 0.08
1st T fasting insulin (mU/l) 5.56 	 0.72 6.48 	 0.74
1st T fasting serum leptin levels (ng/ml)† 28.9 	 3.3 25.8 	 3.6
Weight gain between 1st and 3rd T (kg) 13.5 	 2.68 8.7 	 3.63*
3rd T fasting serum leptin levels (ng/ml)§ 44.1 	 4.72 25.7 	 5.1*
Maternal side placenta mean leptin DNA methylation levels (%) 28.1 	 1.4 29.4 	 1.4
Maternal side placenta leptin mRNA levels (AU) 1.00 	 0.02 1.01 	 0.02
Birth weight (kg) 3.35 	 0.10 3.27 	 0.10
Cord blood leptin levels (ng/ml)‡ 11.1 	 1.2 7.2 	 1.3*
Fetal side placenta mean leptin DNA methylation levels (%) 28.5 	 1.1 28.8 	 1.2
Fetal side placenta leptin mRNA levels (AU) 1.11 	 0.02 1.10 	 0.02
Data are mean 	 SD. IGT was deﬁned as a 2-h glucose 7.8 mmol/l after a 75-g OGTT performed at 24–28
weeks of gestation. AU, arbitrary units; 1st T, ﬁrst trimester of gestation (between weeks 11 and 14); 2nd T,
second trimester of gestation (between weeks 24 and 28); 3rd T, third trimester of gestation (between weeks
36 and 37). *P  0.0001 (unpaired t test). †n  35 (NGT  19 and IGT  16). §n  43 (NGT  23 and
IGT  20). ‡n  39 (NGT  21 and IGT  18).
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trendsinfetalandmaternalsidessuggest-
ing that both placental sides are differ-
ently affected by the mother’s IGT.
Although the biological reasons will not
be simple to explain, we can hypothesize
that the maternofetal glucose transport
dysregulation associated with GDM (18)
contributes to expose both sides of the
placenta to different glucose and insulin
concentrations. In accordance and con-
trary to what we have observed in mater-
nal circulation, cord blood glucose and
insulin levels failed to be correlated with
each other, suggesting that glucose me-
tabolismisfairlydifferentonbothsidesof
the placenta and may thus have a distinc-
tive inﬂuence on the epigenetic proﬁle.
Furthermore, although the 2-h post-
OGTT glycemia explains between 19 and
28%oftheDNAmethylationvariabilityat
theleptingenelocus,asigniﬁcantportion
of the variability remains to be explained
by other factors. Identifying those factors
will be the focus of further studies and
could possibly explain the DNA methyl-
ation differences between both sides of
the placenta.
We have also shown that epigenetic
variability at the leptin gene locus has
functional consequences. However, al-
though placental leptin gene expression
levels have been associated with its circu-
lating concentration, leptin gene DNA
methylation itself has not been associated
with its plasma levels. This raises the
question about the inﬂuence of the pla-
centa on leptin circulating levels. Al-
though this inﬂuence is not obvious to
assess, our results suggest that placental
leptin gene expression could account for
upto16%ofthevarianceofmaternallep-
tin circulating levels. Nevertheless, it is
likely that the impact of placental leptin
DNAmethylationvariabilityonleptincir-
culating levels could have been missed
becauseofthemaskingeffectofotherfac-
tors such as the adipose tissue leptin pro-
duction. In all, the placental contribution
toleptincirculatinglevelsissmallbutsig-
niﬁcant, and the relationship between
leptin DNA methylation and circulating
levels does not seem to be as straightfor-
ward as ﬁrst thought. Nevertheless, the
placental leptin levels could have been af-
fected by its DNA methylation variability,
but the leptin concentration could not be
measured at tissue level in this study. Ad-
ditional studies are therefore needed to
explore this possibility.
It is well accepted that pregnancy is
associated with an increased circulating
leptin concentration (8), although it is
still unclear whether plasma leptin con-
centration shows differences according
to GDM status. A number of studies
have been published reporting either
increased, decreased, or unchanged
concentrations in GDM (19–22). Dis-
crepancies between studies can be ex-
plained by GDM treatment (diet and
exercise versus insulin) as well as moth-
er’s and newborn’s adiposity and weight
gain differences among studies. Never-
theless,ourresultsareinaccordancewith
Figure 2—DNA methylation levels for each CpG site and sample analyzed. *Cytosines that contributed to the summary statistic.
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similarcohortsofwomenwithmildGDM
(23,24) and newborns of mothers with
GDMwithoutinsulintreatment(25),sug-
gestingthatleptinhasbeneﬁcialeffectson
the mother’s glucose disposal and insulin
sensitivity. This could also have short-
and long-term consequences on mothers’
and newborns’ health.
One limitation of the current study is
the lack of signiﬁcant differences in pla-
cental leptin DNA methylation and
mRNA levels between NGT and IGT
groups. Although 48 samples (total 96)
can be considered a large sample size for
DNA methylation and transcriptomic
analyses with this very high phenotyping
quality, it is possible that the study was
short of statistical power to ﬁnd signiﬁ-
cant group differences. Also, we studied
womenwithintermediateglucoseintoler-
anceinsteadofwomenwithGDM.There-
fore, we hypothesize that our results
should at least remain unchanged with
themorestringentGDMdiagnosiscriteria
and may be even more signiﬁcant. Unfor-
tunately, we cannot verify this last hy-
pothesis with our data because most of
the women with glucose perturbations in
our study sample had only a moderate
glucose increase after the second trimes-
ter75-gOGTT.Noneofthemfulﬁlledthe
AmericanDiabetesAssociationcriteriafor
GDM. Nevertheless, the most important
ﬁnding was clearly to have shown signif-
icant correlations between leptin DNA
methylation and 2-h post-OGTT glucose
concentration, a recognized indicator of
glucose metabolism status during
pregnancy.
In summary, our results give a better
understanding of the molecular mecha-
nisms involved in fetal programming as-
sociated with pregnancy-related IGT.
Because DNA methylation can be mitoti-
cally stable, leptin gene DNA methylation
adaptations to IGT and the parallel tran-
scriptional response that we have ob-
served could have profound short- and
long-term phenotypic effects. These ef-
fects could therefore contribute to ex-
plaining why newborns exposed to a
detrimental fetal environment (such as
GDM) have an increased risk of develop-
ing obesity and type 2 diabetes later in
life. Although it is largely speculative, one
hypothesisisthatincreasingmaternalgly-
cemia leads to fetal leptin gene DNA de-
methylation, which leads to higher
mRNA levels and subsequently higher
leptin levels, possibly promoting leptin
resistance and obesity development.
Overall, these data provide supportive
evidence for potential unfavorable mo-
lecular adaptations to the fetal environ-
ment. They also concur to support the
idea that other genes could contribute
to clarifying the concept of molecular
fetal programming.
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